Kim Seongho, Wong Weng Kee
Biostatistics Core, Karmanos Cancer Institute/Wayne State University.
Department of Statistics, UCLA.
Commun Stat Appl Methods. 2019 Mar;26(2):163-173. doi: 10.29220/CSAM.2019.26.2.163. Epub 2019 Mar 31.
Simon's two-stage designs are frequently used in phase II single-arm trials for efficacy studies. In safety studies, a main concern is that there may be too many patients who experience an adverse event. We show that Simon's two-stage designs for efficacy studies can be similarly used to design a two-stage safety study by modifying some of the design parameters. Given the type I and II error rates and the proportion of adverse events experienced in the first stage cohort, we prescribe a procedure whether to terminate the trial or proceed with a stage 2 trial by recruiting additional patients. We study the relationship between a two-stage design with a safety endpoint and an efficacy endpoint and use simulation studies to ascertain their properties. We provide a real-life application and a free R package gen2stage to facilitate direct use of such two-stage designs in a safety study.
西蒙两阶段设计常用于二期单臂试验的疗效研究。在安全性研究中,一个主要问题是可能有太多患者经历不良事件。我们表明,通过修改一些设计参数,用于疗效研究的西蒙两阶段设计可类似地用于设计两阶段安全性研究。给定第一阶段队列中的I型和II型错误率以及经历不良事件的比例,我们规定一个程序,以确定是终止试验还是通过招募更多患者进行第二阶段试验。我们研究了具有安全性终点和疗效终点的两阶段设计之间的关系,并使用模拟研究来确定它们的特性。我们提供了一个实际应用和一个免费的R包gen2stage,以方便在安全性研究中直接使用这种两阶段设计。